# Somnus Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/somnus-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Bedminster, US
- Website: www.somnusthera.com
- Total disclosed funding: $15M
- Latest round: Series A (Feb 11, 2010)
- Investors on record: 2

## About

Somnus Therapeutics Inc. is a biotechnology company focused on developing innovative therapeutic solutions for sleep disorders, aiming to improve patient outcomes through cutting-edge research and development.Founded in 2007 in Bedminster, US, Somnus Therapeutics Inc. specializes in the treatment of sleep disorders. The company has undergone a significant strategic focus on developing therapies that address unmet medical needs in sleep medicine. In February 2010, Somnus closed a Series A financing round, raising USD 15.00 mn led by CTI Life Sciences, with participation from Care Capital. The firm has completed one notable deal to date.Somnus Therapeutics Inc. develops advanced therapeutic products specifically targeting sleep disorders. The company's offerings include innovative treatments designed to enhance sleep quality and overall patient well-being. Through extensive research and development, Somnus aims to provide effective solutions that address various sleep-related issues, thereby meeting the growing demand for effective sleep therapies.The company's revenue model is structured around the successful commercialization of its therapeutic products, which are designed to generate income through sales once they reach the market. The revenue is tied to the adoption of their innovative sleep disorder treatments by healthcare providers and patients, focusing on creating sustainable financial growth aligned with product performance.Looking ahead, Somnus Therapeutics Inc. plans to launch new therapeutic products aimed at improving treatment options for sleep disorders, with specific releases anticipated following current development timelines. The company is also exploring expansion into new geographical markets, particularly in regions where sleep disorders are prevalent and awareness is increasing, by the end of 2025. The recent Series A financing of USD 15.00 mn will be utilized to support these growth initiatives, including research and development for new products and market entry strategies.

## Funding rounds

- Series A, Feb 11, 2010, $15M — Care Capital, CTI Life Sciences

## Investors

- Care Capital (https://capitalatlas.ai/funds/care-capital) — Series A
- CTI Life Sciences (https://capitalatlas.ai/funds/cti-life-sciences) — Series A